Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Exelixis selects BMS as partner for XL184, XL281; terminated

Executive Summary

Less than two months after GlaxoSmithKline passed up its option to license the compounds, oncology-focused biotech Exelixis has found a new partner for Phase III XL184 and Phase I XL281 in Bristol-Myers Squibb, which is getting worldwide rights to the cancer candidates.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register